Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,180,820.35. The trade was a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Andrew Guggenhime also recently made the following trade(s):
- On Tuesday, January 21st, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00.
- On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00.
Vaxcyte Stock Performance
Vaxcyte stock opened at $83.36 on Thursday. The firm's 50-day moving average is $85.88 and its 200-day moving average is $94.65. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The company has a market cap of $10.39 billion, a P/E ratio of -18.12 and a beta of 0.98.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a "buy" rating and a $135.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $14.00 price objective on shares of Vaxcyte in a research note on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $127.71.
Get Our Latest Analysis on PCVX
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of PCVX. Whipplewood Advisors LLC bought a new position in shares of Vaxcyte in the 4th quarter worth about $28,000. Smartleaf Asset Management LLC lifted its position in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new stake in Vaxcyte in the 4th quarter valued at about $41,000. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after purchasing an additional 775 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
